Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
KRAS-targeted mRNA therapeutic vaccine
- Development stage
- Unknown
- Lead developer
- West China Hospital of Sichuan University
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
KRAS-targeted mRNA therapeutic vaccine is an investigational cancer vaccine developed by West China Hospital of Sichuan University. It utilizes messenger RNA (mRNA) technology to encode specific KRAS mutant epitopes, aiming to stimulate the patient's immune system to recognize and attack tumor cells harboring KRAS mutations. The vaccine is currently being evaluated in a Phase 1 clinical trial (ChiCTR2500103833) for patients with advanced KRAS-mutant solid tumors who have failed or are intolerant to standard treatment options. By delivering mRNA that encodes for common KRAS mutations (such as G12D, G12V, or G12C), the vaccine intends to induce a robust T-cell mediated immune response against the oncogenic driver.
- Other names
- KRAS-targeted mRNA therapeutic vaccine
02
Targets
KRAS (Kirsten rat sarcoma viral oncogene homolog)KRAS mutant neoepitope peptide-MHC complexes
Beyond the preview
Go deeper on KRAS-targeted mRNA therapeutic vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on KRAS-targeted mRNA therapeutic vaccine.